Sensei Biotherapeutics (NASDAQ:FTH) Coverage Initiated at HC Wainwright

HC Wainwright started coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) in a note issued to investors on Monday,Benzinga reports. The firm set a “buy” rating and a $60.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 236.70% from the stock’s current price.

Several other equities research analysts have also recently weighed in on FTH. BTIG Research upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. Weiss Ratings assumed coverage on shares of Sensei Biotherapeutics in a research note on Wednesday. They issued a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $60.00.

Get Sensei Biotherapeutics alerts:

View Our Latest Report on Sensei Biotherapeutics

Sensei Biotherapeutics Price Performance

NASDAQ:FTH opened at $17.82 on Monday. The stock has a market cap of $23.88 million, a PE ratio of -0.12 and a beta of -0.25. Sensei Biotherapeutics has a 1 year low of $6.32 and a 1 year high of $36.76.

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.

Recommended Stories

• Five stocks we like better than Sensei Biotherapeutics
• Royal Caribbean’s Best Quarter Ever Still Leaves a Big Question
• Lululemon’s China Backlash May Be Hiding a Bigger Valuation Story
• 3 Inflation-Fighting Stocks Built for Higher Oil Prices
• 3 Biotech Firms With Major Potential Catalysts in the Coming Months

Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.